HopeStage
Back to all studies
CompletedNCT03232112

Exenatide or Placebo and Alcohol Intake in Adults With Alcohol Dependence

About this titleRead the official source — NCT03232112
Medication studyAges 18–70DenmarkAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 70 years.

Listed locations
CopenhagenSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: August 7, 2017
Recruitment status
Completed
Enrollment listed in the registry
152
Sponsor
Anders Fink-Jensen, MD, DMSci
Sponsor type
Individual investigator
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Denmark
Age range
From 18 Years to 70 Years
Official registry ID
NCT03232112
Official title
Show the full official title

Does Glucagon-like Peptide (GLP-1) Receptor Agonist Stimulation Reduce Alcohol Intake in Patients With Alcohol Dependence?

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Copenhagen

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Anders Fink-Jensen, MD, DMSci.

Did this study involve medication?

Yes. The study involved medication, including Exenatide 2 MG Injection and BD PosiFlush (saline).

Who was this study for?

Listed age limits: 18 years to 70 years.

Want to explore more studies?

Explore studies